nonfunctional pituitary adenoma. Pituitary gland
Conditions
Interventions
Intervention 1: Grupe 1 or intervention , will receive sandostatin lar 20 mg q 28 day plus cabergolin 3 – 7 mg per week for 6 months.Cabeergolin frome OSVE company and Sandostatin lar frome NOVARTIS
Sponsors
Iran University of Medical Sciences
Gorgan University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with NFPAs that don't cured by surgery and are SSR –R 1-5 positive ,who have less than 80% resection rate after surgery Patient with NFPAs and are SSR –R 1-5 positive ,that patient who have tumor regrowth after surgery Patient with NFPAs and are SSR –R 1-5 positive ,who previously didn't have received radiotherapy Patient with NFPAs and are SSR –R 1-5 positive ,who previously didn't have received medical therapy with dopamine agonists or somatostatin analogues Patient with NFPAs who don't , SSR –R 1-5 positive
Exclusion criteria
Exclusion criteria: Patients with NFPAs that have cured by surgery ,who have more than 80% resection rate after surgery Patient with NFPAs and , who have emergency surgical indication Patient with NFPAs , who previously have received radiotherapy Patient with NFPAs who have emergency surgical indication Patient with NFPAs ,who previously have received medical therapy with dopamine agonists or somatostatin analogues
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Non functional pituitary adenoma size. Timepoint: Non functional pituitary adenoma size before and 6 months after treatment. Method of measurement: Adenoma size in MRI. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Hypothyroidism. Timepoint: Before and 3 , 6 months after treatment. Method of measurement: Measurement OF T3 ,T4, TSH , Blood sample.;Adrenal insufficiency. Timepoint: Before and 3 , 6 months after treatment. Method of measurement: Serum Cortisol level, blood sample.;Visual field. Timepoint: Before and 6 months after treatment. Method of measurement: Primetry.;Panhypopituitarism. Timepoint: Before and 3 , 6 months after treatment. Method of measurement: Pituitary hormonal assessment in blood sample.;Hypogonadism. Timepoint: Before and 3 , 6 months after treatment. Method of measurement: Measurement LH,FSH ,Esradiol in women and LH,FSH,Testosterone in men, Blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamideh Akbari
Gorgan University of Medical Sciences
Outcome results
None listed